← Back to dossier
Patient handout

Gout (acute flare → urate-lowering therapy)

PRODUCTION

1. Your condition

This handout is for gout (acute flare → urate-lowering therapy). Your care team identified this based on: acute monoarthritis, often 1st mtp (podagra) (acr 2020 fitzgerald; eular 2024).

Other reasons your team may use this plan: polyarticular flare with prior gout (acr 2020 fitzgerald); hyperuricemia + recurrent flares / tophi / urolithiasis (acr 2020 fitzgerald); tophi on exam / dual-energy ct (eular 2024).

2. Your medications

Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.

MedicationStarting doseHowWhenWhat it does
colchicine1.2 mg → 0.6 mg 1h later — low-dose colchicine per AGREE trial (Terkeltaub Arthritis Rheum 2010); ACR 2020 FitzGerald strong; 0.6 mg q12h or daily until resolution
naproxen500 mg BID × 5-7 d; alternative indomethacin 50 mg TID (ACR 2020 FitzGerald first-line)
prednisone40 mg/d × 5 d or 0.5 mg/kg/d taper over 10-14 d (ACR 2020 FitzGerald first-line; EULAR 2024)
anakinra100 mg SC daily × 3-5 d (off-label, ACR 2020 FitzGerald conditional; EULAR 2024)

Plan: Acute gout flare (≤24 h symptom onset)

3. Your action plan

Use these zones to know what to do based on how you feel.

GREENStable, on ULT, at target SUA
If you have:
  • No flares in last 6+ months (ACR 2020 FitzGerald)
  • SUA <6 (or <5 if tophaceous) (ACR 2020 FitzGerald; EULAR 2024)
  • Taking allopurinol/febuxostat as prescribed
Do this:
  • Take ULT every day — never stop because you feel well (ACR 2020 FitzGerald strong)
  • Keep follow-up labs every 6 months (ACR 2020 FitzGerald)
  • Hydrate, limit alcohol and high-fructose drinks (EULAR 2024)
  • Discuss any new medications with your prescriber (some raise SUA) (EULAR 2024)
  • Continue flare prophylaxis (colchicine 0.6 mg daily or NSAID) for at least 6 months after target (ACR 2020 FitzGerald strong)
YELLOWEarly flare or rising SUA
If you have:
  • New joint pain / warmth / swelling
  • SUA rising
  • Missed ULT doses
Do this:
  • DO NOT stop your ULT during a flare (ACR 2020 FitzGerald strong)
  • Start your pre-prescribed flare rescue regimen immediately (colchicine 1.2 mg → 0.6 mg 1 h later, then 0.6 mg q12h; OR NSAID if no CKD; OR prednisone if you have a script) (ACR 2020 FitzGerald)
  • Ice and rest the joint (EULAR 2024)
  • Call your provider within 24 h if not improving
  • Continue flare medication until pain fully resolved (typically 5-7 days) (ACR 2020)
Call your provider if:
  • Flare not improving within 48 h
  • Multiple joints involved
  • Fever (ACR 2020 — rule out septic arthritis)
REDSeptic arthritis suspicion or severe systemic illness
If you have:
  • Fever (>38 C) with hot, swollen joint (ACR 2020 FitzGerald; EULAR 2024)
  • Single joint that is rapidly worsening
  • Cannot bear weight or move joint at all
  • Severe systemic illness
Do this:
  • Go to emergency department now
  • Bring medication list including ULT and flare regimen
  • Tell ED about your gout history but emphasise this might be infection (ACR 2020)
Call your provider if:
  • Always seek emergency care for fever + joint or severe rapid worsening (ACR 2020; EULAR 2024)

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

  • Monoarticular flare with fever, immunocompromise, or atypical features (ACR 2020 FitzGerald; EULAR 2024)(life-threatening)
  • Visible tophus, joint destruction, or recurrent flares despite ULT (ACR 2020 FitzGerald)
  • SE Asian or African American ancestry, CKD ≥3, or thiazide use → high AHS risk (ACR 2020 FitzGerald strong)

5. Follow-up

Lifelong ULT for established gout (ACR 2020 FitzGerald strong); CV risk modification; counsel on diet (alcohol, fructose, organ meats), weight, hydration (EULAR 2024); tophus-specific surgery referral if functional impairment

6. Sources

Guideline: 2020 ACR Guideline for Gout (FitzGerald et al, Arthritis Care Res 2020) + 2024 EULAR Updated Recommendations (Richette et al) + ACP 2017

  1. pubmed.ncbi.nlm.nih.gov/32391934
  2. pubmed.ncbi.nlm.nih.gov/33181081
  3. pubmed.ncbi.nlm.nih.gov/36099211